

MOL #98749

Adhesion GPCRs: from *in vitro* pharmacology to *in vivo* mechanisms

**Kelly R. Monk, Jörg Hamann, Tobias Langenhan, Saskia Nijmeijer, Torsten
Schöneberg and Ines Liebscher**

Department of Developmental Biology, Washington University School of Medicine, St. Louis, Missouri, USA (K.R.M.); Department of Experimental Immunology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands (J.H.); Department of Neurophysiology, Institute of Physiology, University of Würzburg, Würzburg, Germany (T.L.); Department of Medicinal Chemistry/Amsterdam Institute for Molecules, Medicines and Systems (AIMMS), VU University, Amsterdam, The Netherlands (S.N.); and Institute of Biochemistry, Molecular Biochemistry, Medical Faculty, University of Leipzig, Germany (T.S., I.L.)

MOL #98749

Running title: Adhesion GPCR pharmacology

Address correspondence to:

Ines Liebscher, Institute of Biochemistry, Molecular Biochemistry, Medical Faculty, University of Leipzig, Johannisallee 30, 04103 Leipzig, Germany. E-mail: ines.liebscher@medizin.uni-leipzig.de

Number of text pages:	9
Number of tables:	0
Number of figures:	2
Number of references:	62
Number of words:	Abstract: 100
	Introduction: 543
	Discussion (and Conclusion): 2972

List of non-standard abbreviations:

7TM, seven-transmembrane; aGPCR or ADGR, Adhesion G protein-coupled receptor; BAI, brain-specific angiogenesis inhibitors; CELSR, cadherin, EGF LAG seven-pass G-type receptors; CIRL, Calcium-independent receptor of α -latrotoxin; CTF, C-terminal fragment; DMR, dynamic mass redistribution; ECD, extracellular domain; ECM, extracellular matrix; ELTD1, EGF, latrophilin, and seven transmembrane domain containing 1; EMR1, EGF-like module-containing mucin-like hormone receptor-like 1; GAIN, GPCR autoproteolysis-inducing; GPCR, G protein-coupled receptor; GPS, GPCR proteolysis site; GRK, GPCR kinase; ICD, intracellular domain; IUPHAR, International Union of Basic and Clinical Pharmacology; LAT, latrophilin; NTF, N-terminal fragment; PAR, Protease-activated receptor; PKA, protein kinase A; PKC, protein kinase C; TRP, transient receptor potential; TSH, Thyroid-stimulating hormone; VEGF, vascular endothelial growth factor; VLGR1, very large GPCR 1

MOL #98749

Abstract

The adhesion family of G protein-coupled receptors (aGPCRs) comprises 33 human members. aGPCRs are characterized by their enormous size and complex modular structures. While the physiologic importance of many aGPCRs has been clearly demonstrated in recent years, the underlying molecular functions have only recently begun to be elucidated. In this minireview, we present an overview of our current knowledge on aGPCR activation and signal transduction with a focus on the latest findings regarding the interplay between ligand binding, mechanical force, and the tethered agonistic *Stachel* sequence, as well as implications on translational approaches that may derive from understanding aGPCR pharmacology.

MOL #98749

Introduction

G protein-coupled receptors (GPCRs) represent the largest superfamily of receptors in the human genome (Pierce et al., 2002). Based on phylogenetic comparison of their seven-transmembrane spanning (7TM) domain, GPCRs are classified into five families: Glutamate, Rhodopsin, Adhesion, Frizzled/Taste, and Secretin (Lagerström and Schiöth, 2008). Their presence on every cell and responsiveness to diverse stimuli link GPCRs to a great variety of physiological processes.

The 7TM domain with some phylogenetic relation to secretin-like receptors clearly groups adhesion GPCRs (aGPCRs) into the GPCR superfamily. The large extracellular N terminus of aGPCRs is not unique to this class, but is present in all members. A unique feature of the class is a juxtamembrane GPCR proteolysis site (GPS), within the highly conserved GAIN (GPCR autoproteolysis-inducing) domain, that facilitates autocatalytic processing such that the extracellular N-terminal fragment (NTF) and the 7TM/cytoplasmic C-terminal fragment (CTF) are non-covalently associated (Lin et al., 2004; Arac et al., 2012). While the NTF comprises most of the extracellular domain (ECD), the CTF is characteristically composed of a residual ECD, the 7TM domain, and the complete intracellular domain (ICD) (Fig. 1). Historically, orphan aGPCRs have been assigned numbers on discovery, which has led to a rather unstructured assembly of this receptor class. Upon the initiative of the Adhesion GPCR Consortium and the International Union of Basic and Clinical Pharmacology (IUPHAR), a new nomenclature was recently proposed (Hamann et al., 2015). The new names composed of ADGR, a letter, and a number will be presented alongside the old names with first use within this review.

The NTF is responsible for the enormous size of most aGPCRs and presents characteristic modular protein domains. Many of the ~20 different protein domains found in aGPCR NTFs (e.g., cadherin, epidermal growth factor, immunoglobulin, leucine-rich repeat) can mediate contacts with cellular or extracellular matrix (ECM)-associated molecules. So far, about a dozen binding partners have been identified. Notably, these binding partners are structurally highly diverse and have been assigned to a relatively small number of aGPCRs, while the majority of aGPCRs remain orphan with respect to ligand binding (Hamann et al., 2015).

aGPCR family members facilitate cell adhesion, orientation, migration, and positioning in various organ systems, a concept that is based on *in vivo* data obtained in invertebrate and vertebrate models (Hamann et al., 2015). Studies in *Caenorhabditis elegans* and *Drosophila melanogaster* clearly indicate essential roles for the Latrophilin (*ADGRL*) homolog CIRL (Calcium- independent receptor of α - latrotoxin) and the CELSR (cadherin, EGF LAG seven-pass G-type receptors) (*ADGRC*) homolog Flamingo in planar cell and tissue polarity and in neuronal development. Studies in vertebrates unraveled roles of many

MOL #98749

aGPCRs including ELTD1 (EGF, latrophilin, and seven transmembrane domain containing 1) (*ADGRL4*); CD97 (*ADGRE5*), EMR1 (EGF-like module-containing mucin-like hormone receptor-like 1) (*ADGRE1*), GPR124 (*ADGRA2*), CELSRs (*ADGRCs*), BAI1 (brain-specific angiogenesis inhibitors) (*ADGRBs*), GPR56 (*ADGRG1*), GPR64 (*ADGRG2*), GPR126 (*ADGRG6*), and GPR98/VLGR1 (very large GPCR 1) (*ADGRV1*) in various developmental processes, immunity, and tumor progression (Hamann et al., 2015).

Despite their wide distribution and remarkable phenotypes associated with receptor dysfunction, aGPCRs remained 'functional orphans' for a long time (Hamann et al., 2015). Only recently have concepts emerged describing how these non-canonical GPCRs are activated. These models were discussed at the 2014 Lorentz Center Workshop on *Exploring the biology of GPCRs - from in vitro to in vivo*.

***In vitro* pharmacology of aGPCRs**

Demonstration of G-protein coupling as one signaling mode of aGPCRs was a central issue in previous investigations. Early experiments showed that LPHN1 can be co-purified with G α_o (Leliana et al., 1997) while stimulation with alpha-latrotoxin, a known LPHN1 ligand, evokes neurotransmitter release in the presence of extracellular calcium in a phospholipase C-dependent manner (Rahman et al., 1999). Other indirect functional evidence came from second messenger assays (Mogha et al., 2013; Liebscher et al., 2014b; Bohnekamp and Schöneberg, 2011; Gupte et al., 2012) and activated downstream components of G protein-signaling cascades (Iguchi et al., 2008; Yang et al., 2011; Giera et al., 2015; Ward et al., 2011; Bohnekamp and Schöneberg, 2011).

Knock-down and overexpression of G proteins caused a depletion and increase, respectively, of second messenger accumulation (Bohnekamp and Schöneberg, 2011; Liebscher et al., 2014b), strongly supporting the concept of G protein/aGPCR interaction. Final proof of G protein-coupling was provided through [³⁵S]GTP γ S incorporation assays performed on GPR97 (*ADGRG3*) (Gupte et al., 2012) and GPR126 (Liebscher et al., 2014b) under basal and stimulated conditions.

It is important to differentiate between binding partners and agonists for aGPCRs, as ligand-induced receptor activation has been demonstrated in only a few cases. For example, type III collagen can activate RhoA downstream of GPR56 (Luo et al., 2014) and type IV collagen can elevate cAMP via GPR126 (Paavola et al., 2014). A different ECM molecule, Laminin-211, appears to act in a more complex way on GPR126. Under static cell culture conditions, Laminin-211 inhibits cAMP accumulation, while dynamic conditions activate the G s pathway (Petersen et al., 2015) (Fig. 2).

Another intriguing observation on ligand-mediated aGPCR activation was reported by Luo and colleagues (Luo et al., 2014). Here, interaction between collagen III and GPR56

MOL #98749

leads to the removal of the NTF followed by RhoA activation. This finding is consistent with earlier observations on other aGPCRs where NTF removal activates the receptor (Okajima et al., 2010; Paavola et al., 2011; Ward et al., 2011; Stephenson et al., 2013; Liebscher et al., 2014b; Paavola et al., 2014). An activation scenario in which the release of the large ECD triggers receptor activation combines all proposed mechanisms. In this model, an abundant, but likely tissue-specific, ligand binds to the adhesive domains of the NTF, which then abrogates its inhibitory function, facilitated by a natural breakpoint at the cleavage site within the conserved GPS. However, the question remains whether this activation is due to the removal of an inhibitor and/or through the exposition of an agonist. The answer(s) to this question is key, as it will guide future approaches to externally activate or inactivate these receptors.

While the idea of an inhibitory NTF function has been widely discussed (Okajima et al., 2010; Paavola and Hall, 2012; Langenhan et al., 2013; Liebscher et al., 2013), examples among rhodopsin-like GPCRs provide a second model, in which a tethered agonist activates a GPCR upon NTF removal. Protease-activated receptors (PARs) are probably the best known example for this scenario (Vu et al., 1991a; Adams et al., 2011; Hollenberg et al., 2014) (Fig. 2). Similarly, the deletion of the ECD of the (thyrotropin) TSH receptor was shown to lead to constitutive activity of the residual receptor, which was discussed to be either caused by the release of an activating or an inactivating fragment (Zhang et al., 1995; Zhang et al., 2000). However, they concluded that the release of an inhibitory element accounted for their observations. *In vivo* structure-function studies of the *C. elegans* latrophilin receptor LAT-1 initially suggested that the GPS motif can interact with the 7TM domain. *lat-1* is a maternal gene and dynamically expressed during early embryonic development. Analysis of *lat-1* null mutants showed that the receptor governs the establishment of tissue polarity across the developing embryo, and that loss of *lat-1* function results in embryonic lethality (Langenhan et al., 2009). When receptor variants that lacked the 7TM domain but harbored an intact GPS motif, or alternatively contained a chimeric GPS motif but normal 7TM domain were expressed, neither receptor type was able to rescue the polarity defects of *lat-1* mutants individually. However, expression of both defective receptor fragments restored polarity, indicating that the GPS motif and 7TM domain cooperate during receptor activity (Prömel et al., 2012a).

A recent study has now provided compelling evidence that the concept of a tethered peptide agonist is valid for aGPCRs (Liebscher et al., 2014b). Using GPR126 and GPR133 (*ADGRD1*) mutants and receptor-derived synthetic peptide libraries, tethered agonists for these receptors were identified spanning 16 and 13 amino acids, respectively, between the natural GPS cleavage site and TM1 (Fig. 1). Referring to the protruding nature of this agonistic region after exposure, we termed this region the *Stachel* sequence (German word

MOL #98749

for stinger). Due to the tethered nature of the agonist and its resulting 1:1 stoichiometry, high concentrations of the synthetic peptide are required to elicit an intracellular second messenger response. An estimated EC_{50} value of more than 400 μ M was found to elicit G_s -induced cAMP elevation in GPR126- and GPR133-overexpressing cells. *In vivo*, however, a peptide concentration of 100 μ M was sufficient to suppress nervous system defects in *gpr126* mutant zebrafish (Liebscher et al., 2014b). Even though high peptide concentrations were used to stimulate significant receptor activation, each peptide was highly specific for the aGPCR from which it originated. Future studies will focus on the discovery of agonists, antagonists, or inverse agonists that can bind aGPCRs with higher affinity and that can be easily diluted in physiologically inert solutions. This can further promote aGPCR studies in animal models and help to make aGPCRs feasible targets for pharmaceutical therapies. Starting points could be to optimize *Stachel* sequence-derived peptides or to identify small molecule agonists. The first and so far only successfully identified small molecule agonistic compound for an aGPCR is beclomethasone dipropionate for GPR97 (Gupte et al., 2012).

Stachel-induced activation of aGPCRs follows rhodopsin-like GPCR kinetics. Label-free analysis of dynamic mass redistribution (DMR) within the cell allows for real-time monitoring of agonist-induced intracellular signaling. An immediate DMR signal was observed for peptide-induced activation of GPR126, comparable to DMR signals induced by isoprenaline on endogenously expressed β adrenergic receptors (Liebscher et al., 2014b).

Most GPCRs couple to more than one G-protein family, and aGPCRs are no exception. For example, GPR126 and GPR133 have been shown to interact with both G_s and G_i proteins (Liebscher et al., 2013; Mogha et al., 2013). Similarly, GPR64 interacts with G_s and G_q proteins (Kirchhoff et al., 2006), GPR56 can couple to $G_{q/11}$ (Little et al., 2004) as well as $G_{12/13}$ (Iguchi et al., 2008), and VLGR1 can couple to G_i (Hu et al., 2014), G_q , and G_s proteins (Shin et al., 2013). While these studies measured basal G-protein signaling, it will be interesting to examine G protein-coupling specificities upon agonist activation. As aGPCRs interact with β -arrestin 2 (see below), biased signaling, as described for canonical GPCRs, is also very likely for aGPCRs and needs further elucidation.

Classical GPCR signaling can be terminated by homologous (receptor-specific) desensitization or heterologous (via external stimuli) desensitization (Lohse, 1993). The result of both events is receptor internalization followed by either degradation or recycling. Homologous desensitization can be achieved through ubiquitination or phosphorylation of the receptor via second messenger kinases (e.g., protein kinase A and C (PKA, PKC)) or a distinct family of GPCR kinases (GRKs), the latter acting in concert with arrestins (Pierce et al., 2002). There are hints that aGPCRs follow these patterns of signal inactivation. A constitutively active GPR56 mutant enhances interactions with β -arrestin 2 and ubiquitination of the receptor (Paavola et al., 2011). Further, ligand-induced downregulation has been

MOL #98749

demonstrated for CD97 in circulating leukocytes (Karpus et al., 2013). This downregulation of CD97 required shear stress and correlated with an increase in plasma levels of soluble CD97, suggesting that dissociation of the NTF triggers degradation of the CTF of the receptor. Whether this downregulation of CD97 is playing a role in aGPCR activation through revelation of the *Stachel* sequence remains to be examined. Another study shows that GPR56 is efficiently downregulated by stimulation with phorbol 12-myristate 13-acetate (PMA), a PKC activator (Little et al., 2004). These data provide evidence of aGPCR signal termination mechanisms comparable to rhodopsin-like GPCRs. Excitingly, the recently identified peptide agonists allow us to systematically investigate desensitization and downregulation kinetics of aGPCRs.

***In vivo* mechanisms of aGPCR activation**

As noted in the minireview on 'Model organisms in GPCR research' (Langenhan et al., this issue), the first experiments suggesting that GPR126 can couple to G proteins derived from work in zebrafish. Addition of forskolin, an adenylyl cyclase activator, suppresses nervous system defects in *gpr126* zebrafish mutants (Monk et al., 2009; Glenn and Talbot, 2013). Subsequent studies demonstrated that cAMP elevation could also suppress *gpr126* zebrafish mutant ear defects (Geng et al., 2013) and mouse mutant defects (Mogha et al., 2013). Critically, these suggestive *in vivo* studies were complemented by *in vitro* approaches (Mogha et al., 2013; Liebscher et al., 2014b) clearly demonstrating the G_s-coupling ability of GPR126.

Recent studies on GPR126 in zebrafish also shed light on the *in vivo* relevance of *Stachel*-mediated aGPCR activation. Liebscher et al. described a new zebrafish mutant in which two key amino acids in the *Stachel* domain are deleted. Critically, this mutant receptor is cleaved and traffics appropriately to the cell membrane, but the nervous system defect is identical to previously published strong loss-of-function mutants that lack the entire CTF (Liebscher et al., 2014b). Namely, Schwann cells (glial cells in the peripheral nervous system) cannot generate the myelin sheath. Thus, tethered agonist-mediated activation of GPR126 is essential for myelination *in vivo*. Interestingly, the GAIN domain crystal structures of other aGPCRs demonstrate that the tethered agonist is embedded between two beta-sheets of the GAIN domain (Arac et al., 2012). This sequence is deeply buried and likely requires significant structural changes, perhaps mechanical removal of the NTF, to mediate aGPCR activation. At the Lorentz Center workshop in Leiden, a potential mechanism for mechanical NTF removal *in vivo* was proposed (Fig. 2).

During peripheral nerve development, Schwann cells synthesize and secrete ECM proteins that form a basal lamina. ECM proteins in the basal lamina include collagen IV and Laminin-211, known binding partners for GPR126 (Paavola et al., 2014; Petersen et al.,

MOL #98749

2015). Critically, during basal lamina maturation, Laminin-211 polymerizes and this is essential for proper Schwann cell development and myelination (McKee et al., 2012). Petersen et al. reasoned that Laminin-211 polymerization could facilitate GPR126-NTF removal, thereby exposing the tethered agonist to drive myelination. In line with this model, overexpression of wild-type but not non-polymerizing *lama2* (the gene encoding the alpha chain of Laminin-211) could suppress myelin defects in *gpr126* hypomorphic mutants. This, coupled with the dynamic culture assays described above support the notion that Laminin-211 polymerization could be one mechanism that facilitates GPR126-NTF removal *in vivo* (see also Langenhan et al., this issue).

Complementary evidence for mechanical activation of aGPCR signals *in vivo* comes from recent studies on the ADGRL homolog Latrophilin/CIRL of the vinegar fly *D. melanogaster* (Scholz et al., 2015). Here, the aGPCR is resident in mechanosensory neurons, which – upon mechanical stimulation through sound, touch or stretch – respond adequately with an increase in electrical activity. Removal of Latrophilin/CIRL results in a dramatic drop of this input-output relationship leading to profound insensitivity towards mechanical stimulation and blurred signal-to-noise discrimination. Genetic experiments have further indicated that Latrophilin/CIRL may act by modulating ionotropic mechanosensors of the transient receptor potential (TRP) channel family and may impinge on their properties in a mechanostimulus-dependent manner (see also Langenhan et al., this issue). Whether this effect of Latrophilin/CIRL is dependent on NTF, CTF, or both aGPCR fragments acting together, remains to be determined.

How autoproteolysis as a prominent biochemical asset of aGPCRs and prerequisite for NTF removal is linked to signaling is still a conundrum, and may vary for different aGPCRs or even for the same aGPCR in different developmental or cellular contexts. The existence of cleavage-deficient aGPCR homologs due to lack of the consensus GPS site, like GPR123 (*ADGRA1*) or the conserved cleavage motif as in GPR111 (*ADGRF2*) and GPR115 (*ADGRF4*) (Prömel et al., 2012b) suggests that not all aGPCRs rely on a releasable NTF. Further, studies on LAT-1 in *C. elegans* have directly studied this phenomenon *in vivo* using the transgenic complementation assay described above. Intriguingly, autoproteolysis-resistant *lat-1* variants perform indistinguishably from wild-type versions of the receptor, suggesting that separation of NTF and CTF is not necessary for full receptor function (Prömel et al., 2012a). This indicates that not all aGPCRs require a *Stachel sequence* to signal and/or that accessibility of the *Stachel sequence* may not require NTF release.

Additionally, metabotropic function may not be the sole biological signal controlled by aGPCRs. Many aGPCR layouts exhibit large interaction interfaces through their extracellular adhesion domains including the GAIN domain, through which they can form receptor complexes with other transmembrane signaling proteins such as frizzled GPCRs and the

MOL #98749

tetraspanning polarity protein Van Gogh that execute their own signals (Chen et al., 2008; Nishimura et al., 2012). Secondly, aGPCR ECDs may even engage with signaling proteins located on neighboring cells and govern non-cell autonomous signals (Shima et al., 2007; Steimel et al., 2010). In this scenario, aGPCRs act as a ligand rather than a receptor. Finally, emerging evidence also suggests that the NTF and CTF of aGPCRs can have distinct biological functions (Prömel et al., 2012; Patra et al., 2013, Petersen et al., 2015). Continued work is required to more fully understand these non-metabotropic functions of aGPCRs and whether these properties can be modulated in future pharmacological strategies.

Translational implications of aGPCR function

aGPCRs are expressed in various tissues in the human body and play crucial roles in cellular and developmental processes (Hamann et al., 2015). In a time when knowledge on aGPCR structure and function was still limited, aGPCR mRNA variants and/or levels were correlated to biological phenotypes, and animal models have convincingly shown the importance of aGPCRs in development. Two well-known examples are GPR56 and GPR98/VLGR1, where gene mutations are causative for brain malformation (bilateral frontoparietal polymicrogyria) (Piao et al., 2004) and a form of Usher syndrome (Weston et al., 2004), respectively. Moreover, altered aGPCR gene expression is observed in several cancers (Aust et al., 1997; Fukushima et al., 1998; Carson-Walter et al., 2001; Kaur et al., 2003; Kee et al., 2004; Shashidhar et al., 2005; Aust, 2010; Lum et al., 2010; Davies et al., 2011; Favara et al., 2014; Liebscher et al., 2014a), suggest a promising role for these receptors as biomarkers for tumour recognition and possibly even targeting.

With the recent elucidation and engineering of specific aGPCR ligands/agonists as well as antibodies, it became possible to dissect protein function and signaling properties of this receptor family and consequently to associate them with (patho)physiological conditions (e.g. cancer-related processes such as angiogenesis, adhesion, migration, and proliferation). In line with this, expression of GPR56 can inhibit VEGF (vascular endothelial growth factor) production in melanoma cell lines, thereby inhibiting melanoma angiogenesis and growth, a process involving the serine-threonine-proline-rich region in the ECD of GPR56, which leads to a PKC α -dependent signalling cascade (Yang et al., 2011). Similarly, expression of GPR116 (*ADGRF5*) has been shown to promote breast cancer metastasis via activation of G α_q -p63RhoGEF-Rho GTPase pathway (Tang et al., 2013).

It was recently stressed that aGPCRs are frequently mutated in multiple human cancers (O'Hayre et al., 2013). Our improved understanding of receptor function will help to unravel the consequences of these mutations for aGPCR function. Coding region mutations range from the ECD and GAIN domain to the 7TM in aGPCRs. In CELSR1 and CELSR3, cancer-associated mutations in the GAIN domain did not alter receptor processing or

MOL #98749

localization (Arac et al., 2012). It remains open whether these mutations contribute to tumor formation or are just a reflection of the higher tumor mutation rates. Perhaps ECD-mutations hamper cell-cell or cell-matrix interactions due to decreased adhesive capacity (Lagerström and Schiöth, 2008; Paavola and Hall, 2012). It is reasonable to assume that mutations in the ECD region could also affect potential ligand-binding properties or prevent NTF modulation and *Stachel*-mediated receptor activation.

Conclusions

Until recently it was unclear whether aGPCRs signal via G proteins at all. There is now mounting evidence from conventional pharmacological assays (e.g. [³⁵S]GTPγS and second messenger detection) and *in vivo* studies that aGPCRs activate classic G protein-signaling cascades. aGPCRs display similar signaling kinetics and coupling specificity upon activation when compared to rhodopsin-like GPCRs. β-arrestin interaction and ubiquitination of aGPCRs suggests that desensitization mechanisms are comparable to canonical GPCRs. Along these lines, it is likely that aGPCRs can also exhibit biased signaling, although this notion has not yet been formally tested.

Despite these key similarities, aGPCRs are distinct from rhodopsin-like GPCRs in how receptor activation can be initiated (Fig. 2). While the generation of a tethered agonist is an accepted concept for some other GPCRs (e.g., PARs), generation of such an agonist in aGPCRs is not achieved by protease action. Rather, a unique and complex activation mechanism accounts for their stimulation, and we have only started to understand the requirements for this process. This includes binding of an extracellular ligand and, at least for some aGPCRs, potentially mechanical forces that expose a tethered agonist to the 7TM.

GPCRs in general have consistently been of interest to the pharmaceutical world. Their ideal localization at the cell membrane combined with well characterized signaling properties make them excellent drug targets. Due to the plethora of aGPCR-signaling aspects, it is tempting to speculate that there are multiple manners to interfere with aGPCR function. The modulation of ECD-ligand interactions for example could prevent the interaction of the *Stachel* peptide with the 7TM region. Moreover, the 7TM could also be targeted in an allosteric manner to directly modulate receptor activation. Future works will focus on using these principles in *ex vivo*- and *in vivo* settings to elucidate their implications in the development and potential treatment of human diseases.

MOL #98749

Acknowledgements

We would like to thank the organizers and participants of the 2014 Lorentz Center workshop for their critical and constructive discussions, which formed the basis of this review and nourished ideas for future research topics. We further thank the Adhesion-GPCR Consortium (www.adhesiongpcr.org) for providing a platform of open exchange of ideas and discussion of new data.

Authorship Contributions

Wrote or contributed to the writing of the manuscript: Monk, Hamann, Langenhan, Nijmeijer, Schöneberg, and Liebscher

MOL #98749

References

- Adams MN, Ramachandran R, Yau M, Suen JY, Fairlie DP, Hollenberg MD, and Hooper JD (2011) Structure, function and pathophysiology of protease activated receptors. *Pharmacol Ther* **130**:248–282 doi: 10.1016/j.pharmthera.2011.01.003.
- Arac D, Boucard AA, Bolliger MF, Nguyen J, Soltis SM, Südhof TC, and Brunger AT (2012) A novel evolutionarily conserved domain of cell-adhesion GPCRs mediates autoproteolysis. *EMBO J* **31**:1364–1378 doi: 10.1038/emboj.2012.26.
- Aust G (2010) Adhesion-GPCRS in tumorigenesis. *Adv Exp Med Biol* **706**:109–120.
- Aust G, Eichler W, Laue S, Lehmann I, Heldin NE, Lotz O, Scherbaum WA, Dralle H, and Hoang-Vu C (1997) CD97: a dedifferentiation marker in human thyroid carcinomas. *Cancer Res* **57**:1798–1806.
- Bohnekamp J and Schöneberg T (2011) Cell adhesion receptor GPR133 couples to Gs protein. *J Biol Chem* **286**:41912–41916 doi: 10.1074/jbc.C111.265934.
- Carson-Walter EB, Watkins DN, Nanda A, Vogelstein B, Kinzler KW, and St Croix B (2001) Cell surface tumor endothelial markers are conserved in mice and humans. *Cancer Res* **61**:6649–6655.
- Chen W, Antic D, Matis M, Logan CY, Povelones M, Anderson GA, Nusse R, and Axelrod JD (2008) Asymmetric homotypic interactions of the atypical cadherin flamingo mediate intercellular polarity signaling. *Cell* **133**:1093–1105 doi: 10.1016/j.cell.2008.04.048.
- Davies JQ, Lin H, Stacey M, Yona S, Chang G, Gordon S, Hamann J, Campo L, Han C, Chan P, and Fox SB (2011) Leukocyte adhesion-GPCR EMR2 is aberrantly expressed in human breast carcinomas and is associated with patient survival. *Oncol Rep* **25**:619–627 doi: 10.3892/or.2010.1117.
- Favara DM, Banham AH, and Harris AL (2014) A review of ELTD1, a pro-angiogenic adhesion GPCR. *Biochem Soc Trans* **42**:1658–1664 doi: 10.1042/BST20140216.
- Fukushima Y, Oshika Y, Tsuchida T, Tokunaga T, Hatanaka H, Kijima H, Yamazaki H, Ueyama Y, Tamaoki N, and Nakamura M (1998) Brain-specific angiogenesis inhibitor 1 expression is inversely correlated with vascularity and distant metastasis of colorectal cancer. *Int J Oncol* **13**:967–970.
- Geng F, Abbas L, Baxendale S, Holdsworth CJ, Swanson AG, Slanchev K, Hammerschmidt M, Topczewski J, and Whitfield TT (2013) Semicircular canal morphogenesis in the zebrafish inner ear requires the function of gpr126 (lauscher), an adhesion class G protein-coupled receptor gene. *Development* **140**:4362–4374 doi: 10.1242/dev.098061.
- Glenn TD and Talbot WS (2013) Analysis of Gpr126 function defines distinct mechanisms controlling the initiation and maturation of myelin. *Development* **140**:3167–3175 doi: 10.1242/dev.093401.
- Gupte J, Swaminath G, Danao J, Tian H, Li Y, and Wu X (2012) Signaling property study of adhesion G-protein-coupled receptors. *FEBS Lett* **586**:1214–1219 doi: 10.1016/j.febslet.2012.03.014.
- Hamann J, Aust G, Araç D, Engel FB, Formstone C, Fredriksson R, Hall RA, Harty BL, Kirchhoff C, Knapp B, Krishnan A, Liebscher I, Lin H, Martinelli DC, Monk KR, Peeters MC, Piao X, Prömel S, Schöneberg T, Schwartz TW, Singer K, Stacey M, Ushkaryov YA, Vallon M, Wolfrum U, Wright MW, Xu L, Langenhan T, and Schiöth HB (2015) International Union of Basic and Clinical Pharmacology. XCIV. Adhesion G protein-coupled receptors. *Pharmacol. Rev.* **67**:338–367 doi: 10.1124/pr.114.009647.
- Hollenberg MD, Mihara K, Polley D, Suen JY, Han A, Fairlie DP, and Ramachandran R (2014) Biased signalling and proteinase-activated receptors (PARs): targeting inflammatory disease. *Br J Pharmacol* **171**:1180–1194 doi: 10.1111/bph.12544.

MOL #98749

- Hu Q, Dong J, Du H, Zhang D, Ren H, Ma M, Cai Y, Zhao T, Yin X, Yu X, Xue T, Xu Z, and Sun J (2014) Constitutive Galphai coupling activity of very large G protein-coupled receptor 1 (VLGR1) and its regulation by PDZD7 protein. *J Biol Chem* **289**:24215–24225 doi: 10.1074/jbc.M114.549816.
- Iguchi T, Sakata K, Yoshizaki K, Tago K, Mizuno N, and Itoh H (2008) Orphan G protein-coupled receptor GPR56 regulates neural progenitor cell migration via a G alpha 12/13 and Rho pathway. *J Biol Chem* **283**:14469–14478 doi: 10.1074/jbc.M708919200.
- Karpus ON, Veninga H, Hoek RM, Flierman D, van Buul, Jaap D, Vandenakker CC, vanBavel E, Medof ME, van Lier, Rene A W, Reedquist KA, and Hamann J (2013) Shear stress-dependent downregulation of the adhesion-G protein-coupled receptor CD97 on circulating leukocytes upon contact with its ligand CD55. *J Immunol* **190**:3740–3748 doi: 10.4049/jimmunol.1202192.
- Kaur B, Brat DJ, Calkins CC, and Van Meir, Erwin G (2003) Brain angiogenesis inhibitor 1 is differentially expressed in normal brain and glioblastoma independently of p53 expression. *Am J Pathol* **162**:19–27 doi: 10.1016/S0002-9440(10)63794-7.
- Kee HJ, Ahn KY, Choi KC, Won Song J, Heo T, Jung S, Kim J, Bae CS, and Kim KK (2004) Expression of brain-specific angiogenesis inhibitor 3 (BAI3) in normal brain and implications for BAI3 in ischemia-induced brain angiogenesis and malignant glioma. *FEBS Lett* **569**:307–316 doi: 10.1016/j.febslet.2004.06.011.
- Kirchhoff C, Obermann H, Behnen M, and Davies B (2006) Role of epididymal receptor HE6 in the regulation of sperm microenvironment. *Mol Cell Endocrinol* **250**:43–48 doi: 10.1016/j.mce.2005.12.023.
- Lagerström MC and Schiöth HB (2008) Structural diversity of G protein-coupled receptors and significance for drug discovery. *Nat Rev Drug Discov* **7**:339–357 doi: 10.1038/nrd2518.
- Langenhan T, Aust G, and Hamann J (2013) Sticky signaling--adhesion class G protein-coupled receptors take the stage. *Sci Signal* **6**:re3 doi: 10.1126/scisignal.2003825.
- Langenhan T, Prömel S, Mestek L, Esmaeili B, Waller-Evans H, Hennig C, Kohara Y, Avery L, Vakonakis I, Schnabel R, and Russ AP (2009) Latrophilin signaling links anterior-posterior tissue polarity and oriented cell divisions in the *C. elegans* embryo. *Dev Cell* **17**:494–504 doi: 10.1016/j.devcel.2009.08.008.
- Lelianova VG, Davletov BA, Sterling A, Rahman MA, Grishin EV, Totty NF, and Ushkaryov YA (1997) Alpha-latrotoxin receptor, latrophilin, is a novel member of the secretin family of G protein-coupled receptors. *J Biol Chem* **272**:21504–21508.
- Liebscher I, Ackley B, Arac D, Ariestanti DM, Aust G, Bae B, Bista BR, Bridges JP, Duman JG, Engel FB, Giera S, Goffinet AM, Hall RA, Hamann J, Hartmann N, Lin H, Liu M, Luo R, Mogha A, Monk KR, Peeters MC, Prömel S, Ressel S, Schiöth HB, Sigoillot SM, Song H, Talbot WS, Tall GG, White JP, Wolfrum U, Xu L, and Piao X (2014a) New functions and signaling mechanisms for the class of adhesion G protein-coupled receptors. *Ann N Y Acad Sci* doi: 10.1111/nyas.12580.
- Liebscher I, Schön J, Petersen SC, Fischer L, Auerbach N, Demberg LM, Mogha A, Cöster M, Simon K, Rothmund S, Monk KR, and Schöneberg T (2014b) A Tethered Agonist within the Ectodomain Activates the Adhesion G Protein-Coupled Receptors GPR126 and GPR133. *Cell Reports* doi: 10.1016/j.celrep.2014.11.036.
- Liebscher I, Schöneberg T, and Prömel S (2013) Progress in demystification of adhesion G protein-coupled receptors. *Biol Chem* **394**:937–950 doi: 10.1515/hsz-2013-0109.

MOL #98749

- Lin H, Chang G, Davies JQ, Stacey M, Harris J, and Gordon S (2004) Autocatalytic cleavage of the EMR2 receptor occurs at a conserved G protein-coupled receptor proteolytic site motif. *J Biol Chem* **279**:31823–31832 doi: 10.1074/jbc.M402974200.
- Little KD, Hemler ME, and Stipp CS (2004) Dynamic regulation of a GPCR-tetraspanin-G protein complex on intact cells: central role of CD81 in facilitating GPR56-Galpa q/11 association. *Mol Biol Cell* **15**:2375–2387 doi: 10.1091/mbc.E03-12-0886.
- Lohse MJ (1993) Molecular mechanisms of membrane receptor desensitization. *Biochim Biophys Acta* **1179**:171–188.
- Lum AM, Wang BB, Beck-Engeser GB, Li L, Channa N, and Wabl M (2010) Orphan receptor GPR110, an oncogene overexpressed in lung and prostate cancer. *BMC Cancer* **10**:40 doi: 10.1186/1471-2407-10-40.
- Luo R, Jeong S, Yang A, Wen M, Saslowsky DE, Lencer WI, Arac D, and Piao X (2014) Mechanism for adhesion G protein-coupled receptor GPR56-mediated RhoA activation induced by collagen III stimulation. *PLoS One* **9**:e100043 doi: 10.1371/journal.pone.0100043.
- McKee KK, Yang D, Patel R, Chen Z, Strickland S, Takagi J, Sekiguchi K, and Yurchenco PD (2012) Schwann cell myelination requires integration of laminin activities. *J Cell Sci* **125**:4609–4619 doi: 10.1242/jcs.107995.
- Mogha A, Benesh AE, Patra C, Engel FB, Schöneberg T, Liebscher I, and Monk KR (2013) Gpr126 functions in Schwann cells to control differentiation and myelination via G-protein activation. *J Neurosci* **33**:17976–17985 doi: 10.1523/JNEUROSCI.1809-13.2013.
- Monk KR, Naylor SG, Glenn TD, Mercurio S, Perlin JR, Dominguez C, Moens CB, and Talbot WS (2009) A G protein-coupled receptor is essential for Schwann cells to initiate myelination. *Science* **325**:1402–1405 doi: 10.1126/science.1173474.
- Nishimura T, Honda H, and Takeichi M (2012) Planar cell polarity links axes of spatial dynamics in neural-tube closure. *Cell* **149**:1084–1097 doi: 10.1016/j.cell.2012.04.021.
- O'Hayre M, Vazquez-Prado J, Kufareva I, Stawiski EW, Handel TM, Seshagiri S, and Gutkind JS (2013) The emerging mutational landscape of G proteins and G-protein-coupled receptors in cancer. *Nat Rev Cancer* **13**:412–424 doi: 10.1038/nrc3521.
- Okajima D, Kudo G, and Yokota H (2010) Brain-specific angiogenesis inhibitor 2 (BAI2) may be activated by proteolytic processing. *J Recept Signal Transduct Res* **30**:143–153 doi: 10.3109/10799891003671139.
- Paavola KJ and Hall RA (2012) Adhesion G protein-coupled receptors: signaling, pharmacology, and mechanisms of activation. *Mol Pharmacol* **82**:777–783 doi: 10.1124/mol.112.080309.
- Paavola KJ, Sidik H, Zuchero JB, Eckart M, and Talbot WS (2014) Type IV collagen is an activating ligand for the adhesion G protein-coupled receptor GPR126. *Sci Signal* **7**:ra76 doi: 10.1126/scisignal.2005347.
- Paavola KJ, Stephenson JR, Ritter SL, Alter SP, and Hall RA (2011) The N terminus of the adhesion G protein-coupled receptor GPR56 controls receptor signaling activity. *J Biol Chem* **286**:28914–28921 doi: 10.1074/jbc.M111.247973.
- Petersen SC, Luo R, Liebscher I, Giera S, Jeong S, Mogha A, Ghidinelli M, Feltri, M. Laura, Schöneberg T, Piao X, and Monk KR (2015) The Adhesion GPCR GPR126 Has Distinct, Domain-Dependent Functions in Schwann Cell Development Mediated by Interaction with Laminin-211. *Neuron* **85**:755–769 doi: 10.1016/j.neuron.2014.12.057.
- Piao X, Hill RS, Bodell A, Chang BS, Basel-Vanagaite L, Straussberg R, Dobyns WB, Qasrawi B, Winter RM, Innes AM, Voit T, Ross ME, Michaud JL, Descarie J, Barkovich

MOL #98749

- AJ, and Walsh CA (2004) G protein-coupled receptor-dependent development of human frontal cortex. *Science* **303**:2033–2036 doi: 10.1126/science.1092780.
- Pierce KL, Premont RT, and Lefkowitz RJ (2002) Seven-transmembrane receptors. *Nat Rev Mol Cell Biol* **3**:639–650 doi: 10.1038/nrm908.
- Prömel S, Frickenhaus M, Hughes S, Mestek L, Staunton D, Woollard A, Vakonakis I, Schöneberg T, Schnabel R, Russ AP, and Langenhan T (2012a) The GPS motif is a molecular switch for bimodal activities of adhesion class G protein-coupled receptors. *Cell Rep* **2**:321–331 doi: 10.1016/j.celrep.2012.06.015.
- Prömel S, Waller-Evans H, Dixon J, Zahn D, Colledge WH, Doran J, Carlton, Mark B L, Grosse J, Schöneberg T, Russ AP, and Langenhan T (2012b) Characterization and functional study of a cluster of four highly conserved orphan adhesion-GPCR in mouse. *Dev Dyn* **241**:1591–1602 doi: 10.1002/dvdy.23841.
- Rahman MA, Ashton AC, Meunier FA, Davletov BA, Dolly JO, and Ushkaryov YA (1999) Norepinephrine exocytosis stimulated by alpha-latrotoxin requires both external and stored Ca²⁺ and is mediated by latrophilin, G proteins and phospholipase C. *Philos Trans R Soc Lond B Biol Sci* **354**:379–386 doi: 10.1098/rstb.1999.0390.
- Scholz N, Gehring J, Guan C, Ljaschenko D, Fischer R, Lakshmanan V, Kittel RJ, and Langenhan T (2015) The Adhesion GPCR Latrophilin/CIRL shapes mechanosensation. *Cell Rep* doi:10.1016/j.celrep.2015.04.008.
- Shashidhar S, Lorente G, Nagavarapu U, Nelson A, Kuo J, Cummins J, Nikolich K, Urfer R, and Foehr ED (2005) GPR56 is a GPCR that is overexpressed in gliomas and functions in tumor cell adhesion. *Oncogene* **24**:1673–1682 doi: 10.1038/sj.onc.1208395.
- Shima Y, Kawaguchi S, Kosaka K, Nakayama M, Hoshino M, Nabeshima Y, Hirano T, and Uemura T (2007) Opposing roles in neurite growth control by two seven-pass transmembrane cadherins. *Nat Neurosci* **10**:963–969 doi: 10.1038/nn1933.
- Shin D, Lin S, Fu Y, and Ptáček LJ (2013) Very large G protein-coupled receptor 1 regulates myelin-associated glycoprotein via Gas/Gaq-mediated protein kinases A/C. *Proc. Natl. Acad. Sci. U.S.A.* **110**:19101–19106 doi: 10.1073/pnas.1318501110.
- Steimel A, Wong L, Najjarro EH, Ackley BD, Garriga G, and Hutter H (2010) The Flamingo ortholog FMI-1 controls pioneer-dependent navigation of follower axons in *C. elegans*. *Development* **137**:3663–3673 doi: 10.1242/dev.054320.
- Stephenson JR, Paavola KJ, Schaefer SA, Kaur B, Van Meir, Erwin G, and Hall RA (2013) Brain-specific angiogenesis inhibitor-1 signaling, regulation, and enrichment in the postsynaptic density. *J Biol Chem* **288**:22248–22256 doi: 10.1074/jbc.M113.489757.
- Tang X, Jin R, Qu G, Wang X, Li Z, Yuan Z, Zhao C, Siwko S, Shi T, Wang P, Xiao J, Liu M, and Luo J (2013) GPR116, an adhesion G-protein-coupled receptor, promotes breast cancer metastasis via the Galphaq-p63RhoGEF-Rho GTPase pathway. *Cancer Res* **73**:6206–6218 doi: 10.1158/0008-5472.CAN-13-1049.
- Vu TK, Hung DT, Wheaton VI, and Coughlin SR (1991a) Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. *Cell* **64**:1057–1068.
- Vu TK, Wheaton VI, Hung DT, Charo I, and Coughlin SR (1991b) Domains specifying thrombin-receptor interaction. *Nature* **353**:674–677 doi: 10.1038/353674a0.
- Ward Y, Lake R, Yin JJ, Heger CD, Raffeld M, Goldsmith PK, Merino M, and Kelly K (2011) LPA receptor heterodimerizes with CD97 to amplify LPA-initiated RHO-dependent signaling and invasion in prostate cancer cells. *Cancer Res* **71**:7301–7311 doi: 10.1158/0008-5472.CAN-11-2381.

MOL #98749

- Weston MD, Lujendijk, Mirjam W J, Humphrey KD, Moller C, and Kimberling WJ (2004) Mutations in the VLGR1 gene implicate G-protein signaling in the pathogenesis of Usher syndrome type II. *Am J Hum Genet* **74**:357–366 doi: 10.1086/381685.
- Yang L, Chen G, Mohanty S, Scott G, Fazal F, Rahman A, Begum S, Hynes RO, and Xu L (2011) GPR56 Regulates VEGF production and angiogenesis during melanoma progression. *Cancer Res* **71**:5558–5568 doi: 10.1158/0008-5472.CAN-10-4543.
- Zhang M, Tong KP, Fremont V, Chen J, Narayan P, Puett D, Weintraub BD, and Szudlinski MW (2000) The extracellular domain suppresses constitutive activity of the transmembrane domain of the human TSH receptor: implications for hormone-receptor interaction and antagonist design. *Endocrinology* **141**:3514–3517 doi: 10.1210/endo.141.9.7790.
- Zhang ML, Sugawa H, Kosugi S, and Mori T (1995) Constitutive activation of the thyrotropin receptor by deletion of a portion of the extracellular domain. *Biochem Biophys Res Commun* **211**:205–210 doi: 10.1006/bbrc.1995.1797.

MOL #98749

Footnotes

Work in our laboratories was supported by the NIH to K.R.M. [NS079445, HD080601; K.R.M.], the Muscular Dystrophy Association to K.R.M. [293295; K.R.M.], the German Research Council to J.H., T.L., T.S. and I.L. [FOR2149] and the Netherlands Organization for Scientific Research to S.N. [NWO VENI grant 722.014.011].

FIGURE LEGENDS

Fig. 1 Architecture of a prototypic aGPCR

Cartoon depicting structural components of a generic aGPCR. aGPCRs undergo autoproteolytic cleavage in the endoplasmic reticulum at a highly conserved cleavage site that lies within the GPCR proteolysis site (GPS) motif, which is encompassed by the larger GPCR autoproteolysis-inducing (GAIN) domain. This cleavage event divides the receptor into an N-terminal fragment (NTF) and a C-terminal fragment (CTF). The NTF often contains conserved domains found in other proteins (LRR, Ig, EGF) and, along with most of the GAIN domain, comprises the majority of the extracellular domain (ECD). The CTF consists of a residual part of the GAIN domain/ECD, the 7TM domain, and the intracellular domain (ICD). The activating *Stachel* sequence is located within the residual ECD. Figure was adapted to include the *Stachel* sequence from (Liebscher et al., 2014a): New functions and signaling mechanisms for the class of adhesion G protein-coupled receptors, Ines Liebscher, Annals of the New York Academy of Sciences, 2014 Dec;1333:43-64, Copyright © 2014, Copyright owner: Wiley-Blackwell.

Fig. 2 Proposed activation mechanisms of GPCRs

(A) Canonical modes of GPCR activation include the classic binding of an agonist with high affinity to its cognate binding pocket for classic rhodopsin-like GPCRs. An exception lies with the protease-activated receptors (PARs) that expose a cryptic tethered agonistic region upon cleavage by a protease, which then activates the receptor. Synthetic peptides that mimic the tethered peptide sequence can also activate PARs (Vu et al., 1991b; Vu et al., 1991a). (B) Different activation mechanisms are proposed for aGPCRs. Similar to PARs, they possess a cryptic tethered agonist region, the *Stachel* sequence (S). Synthetic peptides derived from the *Stachel* amino acid sequence can activate aGPCRs. The activating *Stachel* sequence could be exposed upon NTF removal, which can then allow for CTF-mediated intracellular function(s) and independent NTF function(s). For GPR126 in peripheral nervous system development, *Stachel* exposure may require interaction with the ECM molecule Laminin-211, which is proposed to direct subsequent mechanical activation (Petersen et al., 2015). Mechanical stimulation of aGPCR has also been suggested for Latrophilin/CIRL in sensory neurons (Scholz et al. 2015), while other studies have shown a direct activation of aGPCRs through interactions with collagens (Luo et al., 2014; Paavola et al., 2014).

Figure 1





Figure 2

A



B

